GenMark Diagnostics, Inc. (NASDAQ:GNMK) management will conduct a conference call for 4th August 2020 at 4:30 PM Eastern Time to discuss financial results and companys performance for 2Q20.
The conference call will also be available live on the website www.genmarkdx.com
Earnings Expectation
GenMark Diagnostics, Inc. is set to announce second quarter earning results on Tuesday 4th August 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, GNMK to report 2Q20 loss of $ 0.09 per share. For the full year, analysts anticipate top line of $ 127.89 million, while looking forward to loss of $ 0.42 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 120.00 million ~ $ 130.00 million
Click Here For More Historical Outlooks Of GenMark Diagnostics, Inc.
GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company offers XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges.
